

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

**VOLUNTARY ANNOUNCEMENT
INCREASE IN SHAREHOLDING BY 1% AND
SHAREHOLDING INCREASE PLAN BY THE CONTROLLING
SHAREHOLDER OF DONG-E-E-JIAO**

This is a voluntary announcement made by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”).

The Company hereby announces that, during the period from 8 November 2024 to 18 December 2024, China Resources Pharmaceutical Investment Company Limited (華潤醫藥投資有限公司) (“**CR Pharmaceutical Investment**”), a wholly-owned subsidiary of the Company, accumulatively acquired an additional 6,424,626 shares of Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) (“**Dong-E-E-Jiao**”) (representing 1.00% of the total share capital of Dong-E-E-Jiao, excluding the repurchased shares of Dong-E-E-Jiao held in the designated account) through centralized bidding transactions on the Shenzhen Stock Exchange trading system (the “**Increase in Shareholding**”).

Dong-E-E-Jiao is a company incorporated in the People’s Republic of China (“**PRC**”). The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement and after the aforesaid Increase in Shareholding, Dong-E-E-Jiao is held as to approximately 10.02% by CR Pharmaceutical Investment, and approximately 23.56% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited (華潤東阿阿膠有限公司); and the Group effectively controls approximately 33.58% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

CR Pharmaceutical Investment and its concert party had not disclosed any plans to increase its shareholding in Dong-E-E-Jiao during the 12-month period prior to this announcement. There were no instances of reduction of shareholding by CR Pharmaceutical Investment and its concert party in Dong-E-E-Jiao during the six-month period prior to this announcement. The Increase in Shareholding had not resulted in any mandatory general offer or change of control of Dong-E-E-Jiao or any material impact on the corporate governance structure or the ongoing operations of Dong-E-E-Jiao, and had not resulted in any non-compliance of relevant listing rules in respect of its shareholding structure.

CR Pharmaceutical Investment intends to further increase its shareholding in Dong-E-E-Jiao during the six-month period commencing from 8 November 2024 through methods permitted by the Shenzhen Stock Exchange (including, without limitation, centralized bidding transactions and bulk transactions) (the “**Shareholding Increase Plan**”), the details of which are set forth as follows:

1. **Purposes:** It is believed that the Shareholding Increase Plan has demonstrated CR Pharmaceutical Investment’s recognition of the value and confidence in the continuous and stable development of Dong-E-E-Jiao, and is expected to boost investor confidence, effectively safeguard investors’ interests, and further promote the continuous, stable and healthy development of Dong-E-E-Jiao.
2. **Amount of the additional shares to be purchased:** The amount of the proposed increase in shareholding during the six-month period commencing from 8 November 2024 shall not be lower than 1% of the total share capital of Dong-E-E-Jiao (i.e. 6,424,644 shares) (which is inclusive of the shares acquired through the Increase in Shareholding as disclosed above) and shall not exceed 1.2% of the total share capital of Dong-E-E-Jiao (i.e. 7,709,573 shares).
3. **Price of the additional shares to be purchased:** There is no pre-determined price range in which such Shareholding Increase Plan will be implemented. The Shareholding Increase Plan will be implemented at a time and in an amount to be determined by CR Pharmaceutical Investment, having regard to the changes in the overall stock market and the trading prices of Dong-E-E-Jiao.
4. **Implementation period:** The Shareholding Increase Plan will be implemented during the six-month period commencing from 8 November 2024. If Dong-E-E-Jiao suspends its trading, the Shareholding Increase Plan will be postponed until after trading resumption and appropriate disclosure will be made accordingly.

5. **Transaction methods:** The Shareholding Increase Plan will be implemented through methods permitted by the Shenzhen Stock Exchange (including, without limitation, centralized bidding transactions and bulk transactions).
6. **Source of funding:** CR Pharmaceutical Investment intends to use its own funds or self-raised funds to conduct the Shareholding Increase Plan.
7. **Undertakings:** CR Pharmaceutical Investment undertakes that it will implement the Shareholding Increase Plan during the aforementioned period, and will not reduce its shareholding in Dong-E-E-Jiao at any time during the implementation period, the six-month after the implementation of the Shareholding Increase Plan, and the statutory restriction period.

This announcement is made by the Company on a voluntary basis to provide information to its shareholders and potential investors. The Shareholding Increase Plan may or may not proceed. Shareholders and potential investors of the Company are reminded to exercise caution in dealing with the securities of the Company.

For ease of reference, the names of the PRC established companies or entities have been included in this announcement in both the Chinese and English languages, and in the event of any inconsistency, the Chinese versions shall prevail.

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Bai Xiaosong
Chairman

PRC, 18 December 2024

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director; Mr. Tao Ran and Mdm. Deng Rong as executive Directors; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors; and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.